Hence, alternatively spliced NRCAM isoforms may present a novel opportunity for targeting neuroblastoma cells using, for example, receptor-targeted nanoparticles containing cancer suppressor miR-186, which has been shown to inhibit tumor growth and immune escape in neuroblastoma [31]. Here, NRCAM is linked to neuroblastoma.